Coller BS - Search Results

1

Administration of abciximab during percutaneous coronary intervention reduces both ex vivo platelet thrombus formation and fibrin deposition: implications for a potential anticoagulant effect of abciximab.

Dangas G, Badimon JJ, Coller BS, Fallon JT, Sharma SK, Hayes RM, Meraj P, Ambrose JA, Marmur JD. Dangas G, et al. Among authors: coller bs. Arterioscler Thromb Vasc Biol. 1998 Aug;18(8):1342-9. doi: 10.1161/01.atv.18.8.1342. Arterioscler Thromb Vasc Biol. 1998. PMID: 9714143 Clinical Trial.

2

Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GPIIb/IIIa receptor. Correlation with bleeding time, platelet aggregation, and blockade of GPIIb/IIIa receptors.

Coller BS, Folts JD, Smith SR, Scudder LE, Jordan R. Coller BS, et al. Circulation. 1989 Dec;80(6):1766-74. doi: 10.1161/01.cir.80.6.1766. Circulation. 1989. PMID: 2598436

3

Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs.

Yasuda T, Gold HK, Fallon JT, Leinbach RC, Guerrero JL, Scudder LE, Kanke M, Shealy D, Ross MJ, Collen D, Coller BS. Yasuda T, et al. Among authors: coller bs. J Clin Invest. 1988 Apr;81(4):1284-91. doi: 10.1172/JCI113446. J Clin Invest. 1988. PMID: 2832448 Free PMC article.

4

Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation.

Gold HK, Coller BS, Yasuda T, Saito T, Fallon JT, Guerrero JL, Leinbach RC, Ziskind AA, Collen D. Gold HK, et al. Among authors: coller bs. Circulation. 1988 Mar;77(3):670-7. doi: 10.1161/01.cir.77.3.670. Circulation. 1988. PMID: 3124974

5

Partial inhibition of platelet aggregation and fibrinogen binding by a murine monoclonal antibody to GPIIIa: requirement for antibody bivalency.

Kutok JL, Coller BS. Kutok JL, et al. Among authors: coller bs. Thromb Haemost. 1994 Dec;72(6):964-72. Thromb Haemost. 1994. PMID: 7537915

6

New antiplatelet agents: platelet GPIIb/IIIa antagonists.

Coller BS, Anderson K, Weisman HF. Coller BS, et al. Thromb Haemost. 1995 Jul;74(1):302-8. Thromb Haemost. 1995. PMID: 8578476 Review.

7

Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis".

Reverter JC, Béguin S, Kessels H, Kumar R, Hemker HC, Coller BS. Reverter JC, et al. Among authors: coller bs. J Clin Invest. 1996 Aug 1;98(3):863-74. doi: 10.1172/JCI118859. J Clin Invest. 1996. PMID: 8698879 Free PMC article.

8

The role of platelets in arterial thrombosis and the rationale for blockade of platelet GPIIb/IIIa receptors as antithrombotic therapy.

Coller BS. Coller BS. Eur Heart J. 1995 Nov;16 Suppl L:11-5. doi: 10.1093/eurheartj/16.suppl_l.11. Eur Heart J. 1995. PMID: 8869013 Review.

9

The anti-GPIIb-IIIa agents: fundamental and clinical aspects.

Coller BS, Anderson KM, Weisman HF. Coller BS, et al. Haemostasis. 1996 Oct;26 Suppl 4:285-93. doi: 10.1159/000217309. Haemostasis. 1996. PMID: 8979134 Review.

10

In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time.

Ammar T, Scudder LE, Coller BS. Ammar T, et al. Among authors: coller bs. Circulation. 1997 Feb 4;95(3):614-7. doi: 10.1161/01.cir.95.3.614. Circulation. 1997. PMID: 9024148

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

288 results

Search Page